Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leszek Lisowski

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 1, 2024
Development of CNS tropic AAV1-like variants with reduced liver-targeting following systemic administration in miceMatthieu Drouyer, Jessica Merjane, Deborah Nazareth, et al.
Nature|January 7, 2014
Selection and evaluation of clinically relevant AAV variants in a xenograft liver modelLeszek Lisowski, Allison P Dane, Kirk Chu, et al.
Human Gene Therapy|February 19, 2009
Transient in vivo beta-globin production after lentiviral gene transfer to hematopoietic stem cells in the nonhuman primateJun Hayakawa, Takahiro Ueda, Leszek Lisowski, et al.
ACS Nano|January 15, 2024
Neuronal Replenishment via Hydrogel-Rationed Delivery of Reprogramming FactorsNegar Mahmoudi, Yi Wang, Niamh Moriarty, et al.
Nature Biotechnology|December 27, 2005
A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interferenceSelda Samakoglu, Leszek Lisowski, Tulin Budak-Alpdogan, et al.
Nature Medicine|April 12, 2016
RNA interference-induced hepatotoxicity results from loss of the first synthesized isoform of microRNA-122 in micePaul N Valdmanis, Shuo Gu, Kirk Chu, et al.
Cells|April 30, 2021
Neurological Disorders Associated with WWOX Germline Mutations-A Comprehensive OverviewEhud Banne, Baraa Abudiab, Sara Abu-Swai, et al.
Nature Communications|September 26, 2020
Engineering domain-inlaid SaCas9 adenine base editors with reduced RNA off-targets and increased on-target DNA editingMinh Thuan Nguyen Tran, Mohd Khairul Nizam Mohd Khalid, Qi Wang, et al.
Molecular Therapy. Methods & Clinical Development|October 27, 2021
Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeysJulien Baruteau, Sharon C Cunningham, Berna Seker Yilmaz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 1, 2020
In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene RegulationAna M Moreno, Xin Fu, Jie Zhu, et al.
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 1, 2024
Development of CNS tropic AAV1-like variants with reduced liver-targeting following systemic administration in miceMatthieu Drouyer, Jessica Merjane, Deborah Nazareth, et al.
Nature|January 7, 2014
Selection and evaluation of clinically relevant AAV variants in a xenograft liver modelLeszek Lisowski, Allison P Dane, Kirk Chu, et al.
Human Gene Therapy|February 19, 2009
Transient in vivo beta-globin production after lentiviral gene transfer to hematopoietic stem cells in the nonhuman primateJun Hayakawa, Takahiro Ueda, Leszek Lisowski, et al.
ACS Nano|January 15, 2024
Neuronal Replenishment via Hydrogel-Rationed Delivery of Reprogramming FactorsNegar Mahmoudi, Yi Wang, Niamh Moriarty, et al.
Nature Biotechnology|December 27, 2005
A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interferenceSelda Samakoglu, Leszek Lisowski, Tulin Budak-Alpdogan, et al.
Nature Medicine|April 12, 2016
RNA interference-induced hepatotoxicity results from loss of the first synthesized isoform of microRNA-122 in micePaul N Valdmanis, Shuo Gu, Kirk Chu, et al.
Cells|April 30, 2021
Neurological Disorders Associated with WWOX Germline Mutations-A Comprehensive OverviewEhud Banne, Baraa Abudiab, Sara Abu-Swai, et al.
Nature Communications|September 26, 2020
Engineering domain-inlaid SaCas9 adenine base editors with reduced RNA off-targets and increased on-target DNA editingMinh Thuan Nguyen Tran, Mohd Khairul Nizam Mohd Khalid, Qi Wang, et al.
Molecular Therapy. Methods & Clinical Development|October 27, 2021
Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeysJulien Baruteau, Sharon C Cunningham, Berna Seker Yilmaz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 1, 2020
In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene RegulationAna M Moreno, Xin Fu, Jie Zhu, et al.
Pageof 10